China3D printingNet December 31st, currently only one has3D printingThe drug company has obtained approval from the U.S. Food and Drug Administration (FDA). In 2015, Aprecia’s drug Spritam broke through the regulatory barriers, so its reputation spread.Now, the company is collaborating with Battelle, a leading research non-profit organization, to expand its pharmaceutical3D printing.
Aprecia has established itself with the development of its so-called ZipDose technology, which is a form of adhesive spraying that can3D printingLarge batches of tablets. Just like ExOne and voxeljet’s other forms of adhesive jetting on the market, Aprecia’s process is also based on the Zcorp adhesive jetting method originally developed by MIT and is now owned by 3D Systems.
The first FDA-approved drug made by the pharmaceutical company with ZipDose was Spritam, an anti-epileptic drug, mainly for people who have difficulty swallowing. 3D printingThe tablets dissolve very quickly and are easy to swallow. Aprecia licenses its technology to pharmaceutical partners to expand its product line.
Battelle is a private non-profit company named after Ohio industrialist Gordon Battelle. The company was founded in 1929 and is dedicated to the research and development of metals and materials science. Now, it conducts research and development, commercializes technology and manages customer laboratories in a wide range of fields. It has played an important role in many historical developments, including the technology behind Xerox, the first nuclear fuel rods used in nuclear reactors, the metal related to the US space program and the first jet engines, fuel for nuclear submarines, and armor. Electroplating of tanks, photovoltaic cells of solar panels, the first reusable insulin injection pen, etc.
Therefore, in terms of R&D, Aprecia seems to be an excellent company.Partners will work together to3D printingThe equipment is promoted from clinical supply to commercial scale. This will include overall improvements in throughput and efficiency.
“Aprecia’s internal equipment design team and its current technology partners have established their global leadership in 3DP commercial-scale manufacturing. The Aprecia leadership team is very optimistic about combining its years of 3DP experience with Battelle’s innovative and engineering talents. “Aprecia CEO Chris Gilmore said. “We believe this partnership will have a long-term impact on Aprecia’s ability to solve drug design challenges, which will bring significant benefits to patients across multiple treatment categories.”
3D printing
The soluble version is called Spritam” alt=” Levetiracetam
3D printing
The soluble version is called Spritam” width=”620″ height=”363″ />
Levetiracetam3D printingThe soluble version is called Spritam.
China3D printingInternet Comment: Although Aprecia is creating the first (so far) only FDA approved3D printingThe manufactured drugs are eye-catching, but the pharmaceuticals3D printingThe realm barely touches any possible surface.In addition to developing more drugs for people with swallowing difficulties, I hope3D printingThe drugs will be tailored to individual patients based on the patient’s weight, height, metabolism, diet and medical history and other variables.Some people imagine that local medicine dispensers can be on demand3D printingPossibility of drugs. In addition, researchers are even exploring new methods for drug delivery through nanorobots and other technologies.
in other words,3D printingThe era of drugs has just begun, and with the joint efforts of Aprecia and Battelle, this pace may accelerate.
China3D printingNet original article!
(Editor in charge: admin)
0 Comments for “Aprecia and Battelle collaborate to expand pharmaceutical 3D printing technology”